Beckman Bidders Revealed
If acquired by either Thermo or Danaher, Beckman Coulter would transform those companies’ clinical diagnostic businesses, which currently participate in more specialized segments of the market. The acquisition would give either of them the resources to gain regulatory approval and commercialize products for personalized medicine. Beckman Coulter’s analytical products would also bolster Thermo’s analytical instrument business.
New York, NY 12/20/10—Bloomberg has reported that Danaher and Thermo Fisher Scientific are among the companies bidding to acquire Beckman Coulter (see IBO 12/15/10), according to three people familiar with the situation. Other companies that may bid include private equity firms KKR & Co., Bain Capital, Apollo Global Management and Blackstone Group. Private equity firms may eventually join forces to make a bid, according to the article. The article cited Leerink Swann analyst Dan Leonard as saying that Beckman Coulter would probably fetch between $90 and $160 per share.
